Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer.

Cancer Biology & Therapy
J Harrison HowardJ Pablo Arnoletti

Abstract

MED1 is a base excision repair enzyme that interacts with the mismatch repair protein MLH1 and maintains genomic integrity by binding methylated DNA and repairing spontaneous deamination events. MED1 mutations have been associated with microsatellite instability and accelerated colorectal cancer (CRC) tumorigenesis. We propose that promoter methylation may serve as an alternative epigenetic mechanism for MED1 gene suppression during sporadic CRC tumorigenesis. Methylation status of the MED1 promoter was investigated in a panel of ovarian and colorectal cancer cell lines. The MED1 promoter region was sequenced following bisulfite treatment and sequence analysis identified a CpG island within the MED1 promoter which is frequently and preferentially methylated (> or =50%) in ovarian and colorectal cancer cell lines with low/reduced MED1 expression. In vitro reversal of methylation restored MED1 expression. In colorectal cancer patients, when MED1 methylation was present, both tumor and matched mucosa were affected equally (mean frequency of methylation 24%) and there was no correlation between methylation and tumor stage. Patients without history of CRC showed significantly lower frequency of methylation (mean 14%, p < 0.05). Decr...Continue Reading

Citations

Feb 1, 2011·Journal of Molecular Cell Biology·Christoph Lahtz, Gerd P Pfeifer
Aug 28, 2012·Epigenomics·Shannon R Dalton, Alfonso Bellacosa
Jul 2, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kyung A KwonHyo-Jin Kim
Jul 25, 2015·Journal of Cellular Biochemistry·Carolina Oliveira GigekMarilia Arruda Cardoso Smith
Jul 26, 2017·World Journal of Gastroenterology : WJG·Mouna TrikiRaja Mokdad-Gargouri
Oct 28, 2015·Oncotarget·Rossella TricaricoAlfonso Bellacosa
Aug 21, 2015·World Journal of Gastroenterology : WJG·Juliana Carvalho Santos, Marcelo Lima Ribeiro
Jun 29, 2012·Oncology Letters·Bing-Rong ZhouDan Luo
Nov 7, 2019·Biomarker Research·Mingzhou GuoJames G Herman
Sep 26, 2020·Biomarker Research·Aiai Gao, Mingzhou Guo
Nov 13, 2013·Cancers·Kankana Bardhan, Kebin Liu
Oct 23, 2019·Free Radical Biology & Medicine·Vlada Koliadenko, Tomasz Wilanowski
Jun 10, 2021·Journal of Molecular Biology·Lakshmi S PiduguAlexander C Drohat
Dec 28, 2019·Experimental and Molecular Pathology·Fawaz N Al-ShaheriNehad M Ayoub

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.